Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21964852 | 0.84 | ALDH1A1 (0.50) | ALDH1A1HPGDSMN1; SMN2ADRB1AR | |
| SCHEMBL21448008 | 0.80 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNAMCOLN3MAPT | |
| SCHEMBL20180492 | 0.78 | MAPT (0.51) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL10353420 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HPGDSMN1; SMN2ADRB1AR | |
| SCHEMBL22765470 | 0.77 | BPTF (0.44) | ALDH1A1SMN1; SMN2ADRB1LMNAMAPT | |
| SCHEMBL3554355 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HPGDSMN1; SMN2ADRB1AR | |
| SCHEMBL21964320 | 0.75 | ACACB (0.38) | MAPTAKR1C3 | |
| SCHEMBL16585816 | 0.73 | ADRB1 (0.52) | ALDH1A1HPGDSMN1; SMN2ADRB1AR | |
| SCHEMBL14983590 | 0.73 | ADRB1 (0.56) | ALDH1A1HPGDSMN1; SMN2ADRB1AR | |
| SCHEMBL18043600 | 0.73 | ADRB1 (0.52) | ALDH1A1HPGDSMN1; SMN2ADRB1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2020-12-10 | — | — | US | disclosed |
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | IMPACT THERAPEUTICS, INC. (CN) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131192-A1 | IMIDAZO[1,2-b]PYRIMIDO[4,5-d]PYRIDAZIN-5(6H)-ONES AND THE USE THEREOF | WEE1, WEE2, CCNE1 | ALDH1A1 1689/4885HPGD 1158/4885SMN1; SMN2 3438/4885 |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | ALDH1A1 1361/4885HPGD 2250/4885SMN1; SMN2 3418/4885 |
| US-11345710-B2 | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | WEE1, WEE2, CCNE1 | ALDH1A1 1689/4885HPGD 1158/4885SMN1; SMN2 3438/4885 |
| US-20200385394-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | ALDH1A1 1361/4885HPGD 2250/4885SMN1; SMN2 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.